Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ACCESS
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
- NCT04904588 ↗
- Active, not recruiting
- Center for International Blood and Marrow Transplant Research
- Focused
We haven't built an HCP commentary report on ACCESS (busulfan, fludarabine and 6 more in Acute Lymphoblastic Leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
HCP commentary on ACCESS so far
What clinicians have said in podcasts, YouTube videos and X posts we have indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Mixed Phenotype Acute Leukemia; Acute Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Lymphoma
- Interventions
- Busulfan; Busulfan; Fludarabine; Total-body irradiation; Cyclophosphamide; Melphalan; PBSC Hematopoietic Stem Cell Transplantation (HSCT); Bone Marrow Hematopoietic Stem Cell Transplantation; Post-transplant Cyclophosphamide; Mesna; Tacrolimus; Mycophenolate Mofetil; Patient-Reported Outcomes
- Arms
- Regimen A (MAC: busulfan and fludarabine, PBSC HCT) · Experimental
- Regimen B (MAC: Fludarabine and TBI; PBSC HCT) · Experimental
- Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT) · Experimental
- Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT) · Experimental
- Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT) · Experimental
- Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT) · Experimental
- Regimen G (MAC: Cyclophosphamide and TBI; BM HCT) · Experimental
- Enrollment
- 300 (estimated)
- Primary outcomes
- Overall Survival
- Sponsor
- Center for International Blood and Marrow Transplant Research with National Marrow Donor Program
- Start
- Sep 30, 2021
- Primary completion
- Aug 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04904588 · updated Mar 18, 2026
Publications
linked from the registry- Jimenez Jimenez AM, Stanek J, Logan BR, Leckrone E, Stefanski HE, Auletta JJ, Spellman SR, Malmberg C, Askar M, Cusatis RN, Shaffer BC, Modi D, Khimani F, Gooptu M, Hamadani M, Maiers M, Bo-Subait S, Bolanos-Meade J, Rao U, Milner J, Abboud R, Jamieson KJ, Carrum G, Dholaria B, Hogan WJ, Reshef R, Kosuri S, Cook RJ, Ballen K, Loren AW, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Shaw BE, Devine SM, Al Malki MM. Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial. Blood Adv. 2026 Aug 19:bloodadvances.2026021081. doi: 10.1182/bloodadvances.2026021081. Online ahead of print. PubMed 42616616
- Auletta JJ, Stanek J, Bo-Subait S, Al Malki MM, Cook R, Gooptu M, Shaffer B, Jimenez AJ, Modi D, Hill JA, Huppler AR, Kou J, Cusatis R, Broglie L, Shaw BE, Stefanski H, Spellman SR, Devine SM. Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial. Blood Adv. 2026 Oct 13;10(19):6551-6563. doi: 10.1182/bloodadvances.2026020882. PubMed 42448319
- Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, Leckrone E, Wu J, Stefanski HE, Auletta JJ, Spellman SR, Malmberg C, Askar M, Cusatis R, Shaffer BC, Modi D, Khimani F, Gooptu M, Hamadani M, Madbouly A, Maiers M, Fingerson S, Cook R, Ballen K, Loren A, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Shaw BE, Devine SM, Jimenez Jimenez AM. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation. J Clin Oncol. 2025 Sep;43(25):2772-2781. doi: 10.1200/JCO-25-00856. Epub 2025 Jun 16. PubMed 40523209